Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 17390 | 538 | 44.1 | 89% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | CCR2 ANTAGONIST | Author keyword | 21 | 69% | 3% | 18 |
| 2 | CCR2 | Author keyword | 14 | 20% | 11% | 60 |
| 3 | CCR2 ANTAGONISTS | Author keyword | 11 | 78% | 1% | 7 |
| 4 | CCR1 | Author keyword | 9 | 31% | 5% | 25 |
| 5 | CCR1 ANTAGONIST | Author keyword | 6 | 71% | 1% | 5 |
| 6 | EXPT STN E336 | Address | 4 | 75% | 1% | 3 |
| 7 | CCR2 INHIBITORS | Author keyword | 3 | 100% | 1% | 3 |
| 8 | 3 AMINOPYRROLIDINE | Author keyword | 2 | 67% | 0% | 2 |
| 9 | HIGH OUTPUT SYNTH | Address | 2 | 67% | 0% | 2 |
| 10 | CLIN IMMUNOL RHEUMATOL F4 218 | Address | 2 | 43% | 1% | 3 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | CCR2 ANTAGONIST | 21 | 69% | 3% | 18 | Search CCR2+ANTAGONIST | Search CCR2+ANTAGONIST |
| 2 | CCR2 | 14 | 20% | 11% | 60 | Search CCR2 | Search CCR2 |
| 3 | CCR2 ANTAGONISTS | 11 | 78% | 1% | 7 | Search CCR2+ANTAGONISTS | Search CCR2+ANTAGONISTS |
| 4 | CCR1 | 9 | 31% | 5% | 25 | Search CCR1 | Search CCR1 |
| 5 | CCR1 ANTAGONIST | 6 | 71% | 1% | 5 | Search CCR1+ANTAGONIST | Search CCR1+ANTAGONIST |
| 6 | CCR2 INHIBITORS | 3 | 100% | 1% | 3 | Search CCR2+INHIBITORS | Search CCR2+INHIBITORS |
| 7 | 3 AMINOPYRROLIDINE | 2 | 67% | 0% | 2 | Search 3+AMINOPYRROLIDINE | Search 3+AMINOPYRROLIDINE |
| 8 | CHEMOKINE ANTAGONIST | 2 | 26% | 1% | 5 | Search CHEMOKINE+ANTAGONIST | Search CHEMOKINE+ANTAGONIST |
| 9 | AZD 4818 | 1 | 100% | 0% | 2 | Search AZD+4818 | Search AZD+4818 |
| 10 | CC CHEMOKINE RECEPTOR 1 ANTAGONIST | 1 | 100% | 0% | 2 | Search CC+CHEMOKINE+RECEPTOR+1+ANTAGONIST | Search CC+CHEMOKINE+RECEPTOR+1+ANTAGONIST |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | TRISUBSTITUTED CYCLOHEXANES | 12 | 86% | 1% | 6 |
| 2 | CHEMOKINE RECEPTOR 2 ANTAGONISTS | 11 | 100% | 1% | 6 |
| 3 | CP 481 715 | 9 | 83% | 1% | 5 |
| 4 | MLN3897 | 8 | 100% | 1% | 5 |
| 5 | CHEMOTACTIC CYTOKINE | 7 | 29% | 4% | 21 |
| 6 | INFLAMED JOINTS | 4 | 30% | 2% | 12 |
| 7 | GENERATION COMPOUNDS | 4 | 75% | 1% | 3 |
| 8 | CCR5 D32 POLYMORPHISM | 3 | 100% | 1% | 3 |
| 9 | ORALLY BIOAVAILABLE CCR2 | 3 | 100% | 1% | 3 |
| 10 | CHEMOKINE RECEPTOR ANTAGONISTS | 3 | 32% | 1% | 7 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Recent developments in CCR2 antagonists | 2009 | 75 | 18 | 44% |
| OPINION Chemokine receptor antagonists: overcoming developmental hurdles | 2009 | 117 | 96 | 28% |
| Chemokine receptor antagonists: Part 1 | 2009 | 65 | 119 | 42% |
| CCR2 Antagonists | 2010 | 45 | 110 | 41% |
| Anti-chemokine small molecule drugs: a promising future? | 2010 | 60 | 73 | 30% |
| Targeting cell migration in rheumatoid arthritis | 2015 | 1 | 68 | 31% |
| Progress in the discovery of CC chemokine receptor 2 antagonists, 2009-2012 | 2013 | 4 | 89 | 70% |
| Chemokines and Their Receptors in Rheumatoid Arthritis Future Targets? | 2005 | 98 | 120 | 35% |
| CC Chemokine Receptors and Chronic Inflammation-Therapeutic Opportunities and Pharmacological Challenges | 2013 | 33 | 410 | 12% |
| CCR1 Antagonists: What Have We Learned From Clinical Trials | 2010 | 30 | 67 | 37% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | EXPT STN E336 | 4 | 75% | 0.6% | 3 |
| 2 | HIGH OUTPUT SYNTH | 2 | 67% | 0.4% | 2 |
| 3 | CLIN IMMUNOL RHEUMATOL F4 218 | 2 | 43% | 0.6% | 3 |
| 4 | GLOBAL DRUG DISCOVERY LEAD DISCOVERY WUPPERTAL | 1 | 100% | 0.4% | 2 |
| 5 | I SMALL | 1 | 100% | 0.4% | 2 |
| 6 | MED CHEM P INFLAMMAT AUTOIMMUN INNOVAT | 1 | 100% | 0.4% | 2 |
| 7 | ORTOPEDIA TRAUMATOL 4 | 1 | 100% | 0.4% | 2 |
| 8 | PREPARAT SEPARAT TECH | 1 | 100% | 0.4% | 2 |
| 9 | BIO ORGAN ANTONIO GONZALEZ | 1 | 50% | 0.2% | 1 |
| 10 | BRANCH MOL BIOL | 1 | 50% | 0.2% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000263989 | EOTAXIN//CCR3//RANTES |
| 2 | 0.0000263366 | MONOCYTE CHEMOATTRACTANT PROTEIN 1//MCP 1 POLYMORPHISM//REGULATED UPON ACTIVATION |
| 3 | 0.0000257607 | IMMUNOBIOL ROBERT H LURIE CANC//EXPT CLIN NEUROL//MS CLIN |
| 4 | 0.0000202700 | CXCR3//CXCL10//CXCL9 |
| 5 | 0.0000175819 | THYMUS AND ACTIVATION REGULATED CHEMOKINE//TARC//CCR4 |
| 6 | 0.0000168796 | BB 10010//CK BETA 8//STEM CELL INHIBITOR |
| 7 | 0.0000164050 | CCL20//CCR6//MACROPHAGE INFLAMMATORY PROTEIN 3 ALPHA |
| 8 | 0.0000162305 | LYMPHOTACTIN//CTAP III//CHEMOKINE STRUCTURE |
| 9 | 0.0000151213 | DUFFY BLOOD GROUP//DARC//DUFFY ANTIGEN |
| 10 | 0.0000116167 | FIBROBLAST LIKE SYNOVIOCYTES//BEREICH MOL MED MUSKULOSKELETALEN SYST//ABORATING MOL BIOL NOVEL THER EUT STRA |